Eden Research ( (GB:EDEN) ) has issued an announcement.
Eden Research plc announced that Derek McAllan, a Non-Executive Director, has purchased 241,588 ordinary shares in the company, increasing his total shareholding to 843,627 shares, representing 0.16% of the company’s issued share capital. This transaction highlights confidence in the company’s strategic direction and its focus on expanding its market presence in sustainable agriculture through innovative biopesticide solutions.
More about Eden Research
Eden Research plc is a UK-listed company specializing in sustainable biopesticides and biocontrol technology. It develops innovative biopesticide products and natural microencapsulation technologies for the global crop protection, animal health, and consumer products industries. Eden’s products, which include Mevalone, Novellus, Cedroz, and Ecovelex, are based on plant-derived active ingredients and are used primarily on high-value fruits and vegetables. The company is recognized for its contributions to the green economy, deriving 100% of its revenue from sustainable products and services.
YTD Price Performance: -20.25%
Average Trading Volume: 682,020
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £16.8M
See more data about EDEN stock on TipRanks’ Stock Analysis page.